Zydus Lifesciences and Lupin on Friday announced signing of licensing and supply agreement to market Zydus' novel drug Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India.Under the terms of this agreement, Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS.Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them.Lupin will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.With a once-daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden, and offers greater convenience for patients.'Saroglitazar Mg which is one of the critical treatments for patients with NAFLD and NASH has substantially improved the patients’ quality of life.

Zydus Lifesciences和羽扇豆周五宣布签署许可证和供应协议，销售Zydus的新药Saroglitazar Mg，用于治疗印度的非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）。根据条款本协议，Lupin将拥有以LINVAS品牌在印度共同销售该产品的半专有权.Zydus以Lipaglyn和Bilypsa品牌推出该药物，并将继续销售。Lupin将根据实现预定义的里程碑支付Zydus的前期许可费和里程碑付款。每天一次，4mg剂量的方案，Saroglitazar Mg可以更好地依从性，减少药丸负担，并为患者提供更大的便利Saroglitazar Mg是NAFLD和NASH患者的关键治疗方法之一，大大提高了患者的生活质量。

We are pleased to join hands with Lupin to enable access to this novel drug and thereby expand the reach,' said Dr. Sharvil Patel, MD of Zydus.'This partnership reaffirms our commitment to grow and expand our offerings to meet unmet needs of patients in India. This partnership will further enhance our gastroenterology portfolio, offering better access to healthcare options to our patients and medical professionals,' said Nilesh Gupta, MD of Lupin.Zydus has been expanding access of its novel therapies through licensing agreements with other pharmaceutical companies.

Zydus博士Sharvil Patel博士说，我们很高兴与羽扇豆一起使用，以便能够获得这种新药，从而扩大使用范围这种伙伴关系重申了我们致力于增长和扩展我们的产品，以满足印度患者未满足的需求。Lupin.Zydus医学博士Nilesh Gupta说，这种合作关系将进一步加强我们的胃肠病学组合，为我们的患者和医疗专业人员提供更好的医疗保健选择.Zydus一直通过与其他制药公司的许可协议扩大其新型疗法的使用范围。

The company early this week entered into licensing agreement with Sun Pharma to co-market its triglycerides lowering drug Desidustat.In India, NAFLD is not only a concern for obese or patients with Diabetes Mellitus, but it has also been observed that NAFLD can develop in the absence of obesity, which is termed 'lean' NAFLD.

本周早些时候，该公司与Sun Pharma签订了许可协议，共同销售其降低甘油三酯的药物Desidustat。在印度，NAFLD不仅是肥胖或糖尿病患者的关注点，而且还观察到NAFLD可以在没有肥胖，这被称为“瘦”NAFLD。

The nu.

nu。